Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11290879 | 0.98 | CYP1A2 (0.50) | CYP1A2SIGMAR1HSD11B1L3MBTL1 | |
| SCHEMBL1678376 | 0.90 | — | — | |
| SCHEMBL9450346 | 0.84 | CYP1A2 (0.42) | CYP1A2SIGMAR1 | |
| SCHEMBL11903669 | 0.82 | CYP1A2 (0.31) | CYP1A2 | |
| SCHEMBL6877800 | 0.81 | CYP1A2 (0.46) | CYP1A2SIGMAR1 | |
| SCHEMBL11903854 | 0.81 | CYP1A2 (0.34) | CYP1A2 | |
| SCHEMBL11903948 | 0.79 | — | — | |
| SCHEMBL11903962 | 0.78 | CYP1A2 (0.50) | CYP1A2 | |
| SCHEMBL12499522 | 0.77 | CYP1A2 (0.37) | CYP1A2SIGMAR1 | |
| SCHEMBL27572979 | 0.76 | CYP1A2 (0.48) | CYP1A2SIGMAR1HSD11B1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011109470-A1 | HETEROARYL NITRILE COMPOUNDS USEFUL AS INHIBITORS OF CATHEPSIN-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-09 | — | — | WO | claimed |
| US-8802698-B2 | 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds as mu opioid receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2011109470-A1 | HETEROARYL NITRILE COMPOUNDS USEFUL AS INHIBITORS OF CATHEPSIN-S | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-09 | — | — | WO | disclosed |
| US-4198429-A | BRONCHOSPASMOLYTIC | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-04-15 | — | — | US | disclosed |
| US-4066641-A | METHOD FOR CYCLIZATION TO GIVE CEPHEM RING | HAMASHIMA YOSHIO | 1978-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080855-A1 | 8-AZABICYCLO[3.2.1]OCTYL-2-HYDROXYBENZAMIDE COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRD1, OPRK1 | CYP1A2 190/4885SIGMAR1 6/4885HSD11B1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.